Value of Octreoscan and 18FDG-PET for Clinical Prognosis of Patients with Neuroendocrine Neoplasms

#1317

Introduction: Despite the existence of biological markers of aggressiveness, the clinical course of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NEN) remains difficult to predict. Discrepancies between imaging data generated with 111In-pentetreotide scintigraphy (SRS) and 18 F-FDG-PET could reflect the degree of cellular de-differentiation.

Aim(s): To test the overall prognostic value of the combined use of these two imaging modalities.

Materials and methods: NEN patients with both types of studies were identified retrospectively from the SwissNET database. Disease evolution was correlated with functional imaging results.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Gouffon M

Authors: Gouffon M, Prior J, Ratib O, Krause T, Pralong F,

Keywords: 111In-pentetreotide scintigraphy, 18F-FDG-PET, prognosis, clinical course,